Yiğit Ulviye, Erdenöz Serkan, Uslu Unal, Oba Ersin, Cumbul Alev, Cağatay Halil, Aktaş Samil, Eskicoğlu Emiray
Bakırköy Dr. Sadi Konuk Training and Research Hospital Clinics of Eye Diseases, Istanbul, Turkey.
Mol Vis. 2011 Apr 26;17:1024-33.
This study applies treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination.
Thirty adult Wistar albino rats were divided into five groups after retinal ischemia was induced by elevating the intraocular pressure to 120 mmHg. The groups were as follows: group 1: control; group 2: acute retinal ischemia (ARI) model but without treatment group; group 3: memantine (MEM) treatment group; group 4: HBO therapy group; and group 5: brimonidine treatment (BRI) group. In the control group, right eyes were cannulated with a 30-gauge needle and removed without causing any intraocular pressure change. The ARI group was an acute retinal ischemia model, but without treatment. In the MEM group, animals were given a unique dose of intravenous 25 mg/kg memantine by the tail vein route after inducing ARI. In the HBO group, at 2 h following ARI, HBO treatment was applied for nine days. In the BRI group, a 0.15% brimonidine tartrate eye drop treatment was applied twice a day (BID) for seven days before ARI. Twenty-one days after establishing ischemia reperfusion, the right eyes were enucleated after the cardiac gluteraldehyde perfusion method, and then submitted to histological evaluation.
On average, the total retinal ganglion cell number was 239.93 ± 8.60 in the control group, 125.14 ± 7.18 in the ARI group, 215.89 ± 8.36 in the MEM group, 208.69 ± 2.05 in the HBO group, and 172.27 ± 8.16 in the BRI group. Mean apoptotic indexes in the groups were 1.1 ± 0.35%, 57.71 ± 0.58%, 23.57 ± 1.73%, 15.63 ± 0.58%, and 29.37 ± 2.55%, respectively.
The present study shows that memantine, HBO, and brimonidine therapies were effective in reducing the damage induced by acute ischemia reperfusion in the rat retina. Our study suggests that these treatments had beneficial effects due to neuroprotection, and therefore may be applied in clinical practice.
本研究将治疗方法应用于遭受急性缺血再灌注损伤的大鼠视网膜,并通过组织病理学检查比较美金刚、高压氧(HBO)疗法和溴莫尼定的疗效。
将30只成年Wistar白化大鼠通过将眼压升高至120 mmHg诱导视网膜缺血后分为五组。分组如下:第1组:对照组;第2组:急性视网膜缺血(ARI)模型但未治疗组;第3组:美金刚(MEM)治疗组;第4组:HBO疗法组;第5组:溴莫尼定治疗(BRI)组。在对照组中,用30号针头插入右眼并摘除,不引起任何眼压变化。ARI组为急性视网膜缺血模型,但未治疗。在MEM组中,在诱导ARI后通过尾静脉途径给动物静脉注射单次剂量25 mg/kg美金刚。在HBO组中,在ARI后2小时,进行9天的HBO治疗。在BRI组中,在ARI前7天每天两次(BID)应用0.15%酒石酸溴莫尼定滴眼液治疗。在建立缺血再灌注21天后,采用心脏戊二醛灌注法摘除右眼,然后进行组织学评估。
对照组平均视网膜神经节细胞总数为239.93±8.60,ARI组为125.14±7.18,MEM组为215.89±8.36,HBO组为208.69±2.05,BRI组为172.27±8.16。各组的平均凋亡指数分别为1.1±0.35%、57.71±0.58%、23.57±1.73%、15.63±0.58%和29.37±2.55%。
本研究表明,美金刚、HBO和溴莫尼定疗法在减轻大鼠视网膜急性缺血再灌注诱导的损伤方面是有效的。我们的研究表明,这些治疗由于具有神经保护作用而具有有益效果,因此可能应用于临床实践。